To see this page, please, enable javaScript and styleSheets on your browser: Tools -> Internet Options ...
Reload !
Gene ATXN2LTABLE OF CONTENTS / OPEN CLOSE ALL PARAGRAPHS
Summary back to top
Compact gene diagram back to top
574 supporting clones for gene ATXN2L back to top
cDNA accession
Links to the sequence
Tissue

most 5' clones
in red
Match
mRNA
From bp
to bp
in mRNA
From bp
to bp
in accs.
Clone encodes
complete protein
(with AA variation)
Features Anomalies
detected by
AceView
Accession
match over
(% length)
Base differences
relative to genome
(% identity)
BU554112 ovary, teratocarcinoma, cell line ATXN2L.a 1 to 728 1 to 736   tiling clone,   736/941
(78 %)
13 diff
(98.7 %id)
AJ317972   ATXN2L.a 94 to 3985 1 to 3893   tiling clone,   3893/3893
(100 %)
7 diff
(99.9 %id)
NM_148414.1   ATXN2L.a 94 to 4073 1 to 3980   RefSeq, AAA Possibly primed on the genome, locally A rich (21/24 A in genome downstream of last aligned base) 3980/3980
(100 %)
2 diff
(100.0 %id)
DR159445 human embryonic stem cells differentiated toan early endodermal cell type ATXN2L.a 2593 to 3391 1 to 799       799/799
(100 %)
0 diff
(100 %id)
H16146 breast ATXN2L.a 3056 to 3399 1 to 347       347/414
(83 %)
7 diff
(98.4 %id)
BI023921 marrow ATXN2L.a 3208 to 3398 198 to 9       190/199
(95 %)
0 diff
(100 %id)
H15838 breast ATXN2L.a 3779 to 4073 295 to 1   tiling clone,   295/295
(100 %)
0 diff
(100 %id)
AJ317970   ATXN2L.b 1 to 4366 1 to 4360 T745S P782T tiling clone, AAA Possibly primed on the genome, locally A rich (21/24 A in genome downstream of last aligned base) 4360/4360
(100 %)
19 diff
(99.6 %id)
NM_007245.2   ATXN2L.b 1 to 4366 1 to 4366 exact RefSeq, AAA Possibly primed on the genome, locally A rich (21/24 A in genome downstream of last aligned base) 4366/4366
(100 %)
2 diff
(100.0 %id)
BF689710 melanotic melanoma, high MDR (cell line), skin ATXN2L.b 2155 to 2947 1 to 783   tiling clone,   783/796
(98 %)
21 diff
(97.4 %id)
CB594467 Blood, promyelocytic leukemia ATXN2L.b 2762 to 3566 1 to 815       815/869
(93 %)
23 diff
(97.4 %id)
CN394679 embryonic stem cells, cell lines H1, H7, andH9 ATXN2L.b 2829 to 3360 1 to 532       532/532
(100 %)
2 diff
(99.7 %id)
CR991240 T-Lymphocytes ATXN2L.b 2875 to 3405 1 to 531       531/536
(99 %)
1 diff
(99.9 %id)
BQ706788 Spleen ATXN2L.b 2979 to 3761 1 to 786       786/956
(82 %)
22 diff
(97.7 %id)
BE255654 eye, retinoblastoma ATXN2L.b 2990 to 3658 1 to 685       685/708
(96 %)
41 diff
(94.3 %id)
CX782459 human embryonic stem cells ATXN2L.b 3116 to 3884 1 to 769   fully sequenced, Possibly primed on the genome, locally A rich (21/24 A in genome downstream of last aligned base) 769/769
(100 %)
1 diff
(99.9 %id)
AL042338 testis ATXN2L.b 3162 to 3555 1 to 391       391/391
(100 %)
8 diff
(98.0 %id)
BI260258 cervical carcinoma cell line, cervix ATXN2L.b 3172 to 3804 1 to 635       635/709
(89 %)
10 diff
(98.6 %id)
BM480319 eye, retinoblastoma ATXN2L.b 3206 to 4068 1 to 885       885/1170
(75 %)
44 diff
(96.3 %id)
BQ213761 embryonal carcinoma, cell line, testis ATXN2L.b 3261 to 4112 1 to 858   tiling clone,   858/863
(99 %)
15 diff
(98.3 %id)
BM918299 blood, natural killer cells, cell line ATXN2L.b 3346 to 4017 1 to 676       676/1184
(57 %)
13 diff
(99.0 %id)
H49705 liver and spleen ATXN2L.b 3374 to 3558 1 to 184       184/184
(100 %)
5 diff
(97.3 %id)
CT004382 T-Lymphocytes ATXN2L.b 3398 to 4078 1 to 681   tiling clone,   681/682
(99 %)
1 diff
(99.9 %id)
BE900167 choriocarcinoma, placenta ATXN2L.b 3431 to 3877 1 to 445       445/445
(100 %)
2 diff
(99.6 %id)
AV752604 Pituitary ATXN2L.b 3451 to 4082 1 to 632       632/670
(94 %)
28 diff
(95.9 %id)
TI_149313684   ATXN2L.b 3461 to 4366 988 to 85   tiling clone, AAA Possibly primed on the genome, locally A rich (21/24 A in genome downstream of last aligned base) 904/993
(91 %)
22 diff
(97.8 %id)
AA393745   ATXN2L.b 3472 to 3933 15 to 476       462/476
(97 %)
6 diff
(98.8 %id)
BQ955766 sciatic nerve ATXN2L.b 3477 to 4201 1 to 740       740/975
(75 %)
25 diff
(97.5 %id)
BM931034 eye, fetal eyes, lens, eye anterior segment,optic nerve, retina, Retina Foveal and Macular, RPE andChoroid ATXN2L.b 3525 to 3909 1 to 385   fully sequenced, Possibly primed on the genome, locally A rich (21/24 A in genome downstream of last aligned base) 385/385
(100 %)
0 diff
(100 %id)
AA299370 uterus ATXN2L.b 3551 to 3723 1 to 173       173/173
(100 %)
1 diff
(99.5 %id)
BQ049340 lymph, lymphoma, cell line ATXN2L.b 3552 to 4327 795 to 1     Submitted on the opposite strand 795/909
(87 %)
31 diff
(96.6 %id)
BE258884 eye, retinoblastoma ATXN2L.b 3563 to 4127 1 to 560       560/590
(94 %)
18 diff
(97.0 %id)
R38449 placenta ATXN2L.b 3565 to 3924 1 to 372       372/410
(90 %)
18 diff
(95.7 %id)
AA325389 brain, cerebellum ATXN2L.b 3581 to 3841 1 to 261       261/261
(100 %)
1 diff
(99.7 %id)
W58707 heart ATXN2L.b 3584 to 4124 1 to 547       547/547
(100 %)
12 diff
(97.9 %id)
AA322839 brain, cerebellum ATXN2L.b 3586 to 3841 1 to 257       257/257
(100 %)
4 diff
(98.5 %id)
BG749562 eye, normal pigmented retinal epithelium ATXN2L.b 3594 to 4166 1 to 577       577/585
(98 %)
6 diff
(99.0 %id)
BG249961 adenocarcinoma, cell line, Liver ATXN2L.b 3659 to 4368 1 to 707       707/721
(98 %)
25 diff
(96.6 %id)
TI_149281977   ATXN2L.b 3660 to 4366 807 to 101   AAA Possibly primed on the genome, locally A rich (21/24 A in genome downstream of last aligned base) 707/707
(100 %)
8 diff
(98.9 %id)
CB305544 lung, Primary Lung Cystic Fibrosis EpithelialCells ATXN2L.b 3672 to 4366 713 to 19   AAA Possibly primed on the genome, locally A rich (21/24 A in genome downstream of last aligned base) 695/695
(100 %)
0 diff
(100 %id)
BF690259 melanotic melanoma, high MDR (cell line), skin ATXN2L.b 3680 to 4296 655 to 29       839/904
(92 %)
31 diff
(96.6 %id)
TI_154020759   ATXN2L.b 3683 to 4358 763 to 88   AAA Possibly primed on the genome, locally A rich (21/24 A in genome downstream of last aligned base) 676/679
(99 %)
0 diff
(100 %id)
CA439694 lung, Metastatic Chondrosarcoma ATXN2L.b 3684 to 4361 697 to 19   AAA Possibly primed on the genome, locally A rich (21/24 A in genome downstream of last aligned base) 679/679
(100 %)
1 diff
(99.9 %id)
AV749859 Pituitary ATXN2L.b 3688 to 4238 1 to 545       545/548
(99 %)
15 diff
(97.3 %id)
BQ446159 Knee, Osteoarthritic Cartilage ATXN2L.b 3700 to 4361 680 to 19   AAA Possibly primed on the genome, locally A rich (21/24 A in genome downstream of last aligned base) 662/662
(100 %)
3 diff
(99.6 %id)
BM702337.
matches multiple genes
eye, optic nerve ATXN2L.b 3704 to 4348 1 to 644     also hits gene SLC39A3andDIRAS1 644/644
(100 %)
1 diff
(99.9 %id)
BQ186144 eye, fetal eyes, lens, eye anterior segment,optic nerve, retina, Retina Foveal and Macular, RPE andChoroid ATXN2L.b 3705 to 4366 1 to 662   AAA Possibly primed on the genome, locally A rich (21/24 A in genome downstream of last aligned base) 662/662
(100 %)
1 diff
(99.9 %id)
BU679737 lung ATXN2L.b 3760 to 4366 626 to 19   AAA Possibly primed on the genome, locally A rich (21/24 A in genome downstream of last aligned base) 608/608
(100 %)
5 diff
(99.2 %id)
CA438607 lung, Metastatic Chondrosarcoma ATXN2L.b 3760 to 4358 620 to 22   AAA Possibly primed on the genome, locally A rich (21/24 A in genome downstream of last aligned base) 599/602
(99 %)
0 diff
(100 %id)
CD623950   ATXN2L.b 3771 to 4363 603 to 10       594/604
(98 %)
0 diff
(100 %id)
AW848391 colon ATXN2L.b 3792 to 4272 481 to 1       481/481
(100 %)
2 diff
(99.6 %id)
BI257835 cervical carcinoma cell line, cervix ATXN2L.b 3803 to 4310 1 to 509       509/553
(92 %)
16 diff
(97.2 %id)
BF813637 colon_ins ATXN2L.b 3820 to 4203 384 to 1     Submitted on the opposite strand 384/384
(100 %)
4 diff
(99.0 %id)
CA439732 lung, Lung Focal Fibrosis ATXN2L.b 3840 to 4361 540 to 19   AAA Possibly primed on the genome, locally A rich (21/24 A in genome downstream of last aligned base) 522/522
(100 %)
1 diff
(99.9 %id)
BF813514 colon_ins ATXN2L.b 3848 to 4203 356 to 1     Submitted on the opposite strand 356/363
(98 %)
1 diff
(99.8 %id)
TI_159695422   ATXN2L.b 3851 to 4361 590 to 80   AAA Possibly primed on the genome, locally A rich (21/24 A in genome downstream of last aligned base) 511/1023
(49 %)
14 diff
(98.7 %id)
BU729119.
matches multiple genes
eye, optic nerve ATXN2L.b 3851 to 4366 534 to 19   AAA Possibly primed on the genome, locally A rich (21/24 A in genome downstream of last aligned base), also hits gene SLC39A3andDIRAS1 516/526
(98 %)
0 diff
(100 %id)
CX782385 human embryonic stem cells ATXN2L.b 3854 to 4361 536 to 29   fully sequenced, AAA Possibly primed on the genome, locally A rich (21/24 A in genome downstream of last aligned base) 508/508
(100 %)
4 diff
(99.3 %id)
CA428244 Bone, Subchondral Bone ATXN2L.b 3854 to 4361 526 to 19   AAA Possibly primed on the genome, locally A rich (21/24 A in genome downstream of last aligned base) 508/508
(100 %)
1 diff
(99.9 %id)
AA304814 retina ATXN2L.b 3856 to 4010 9 to 163     Submitted on the opposite strand 155/163
(95 %)
6 diff
(96.4 %id)
BX393811 Neuroblastoma Cot 25-normalized ATXN2L.b 3857 to 4368 1 to 512       512/512
(100 %)
10 diff
(98.1 %id)
BI261936 lymph, lymphoma, cell line ATXN2L.b 3860 to 4250 392 to 2       391/417
(93 %)
0 diff
(100 %id)
AI095194 B-cell, chronic lymphotic leukemia ATXN2L.b 3873 to 4329 457 to 1       457/457
(100 %)
0 diff
(100 %id)
BM684511 eye, fetal eyes, lens, eye anterior segment,optic nerve, retina, Retina Foveal and Macular, RPE andChoroid ATXN2L.b 3879 to 4360 501 to 20   fully sequenced, AAA Possibly primed on the genome, locally A rich (21/24 A in genome downstream of last aligned base) 482/482
(100 %)
0 diff
(100 %id)
BC144269 Pooled, cerebellum, kidney, placenta,testis, lung, colon, liver, heart, thyroid, bladder,uterus, PCR rescued clones ATXN2L.c 1 to 3514 1 to 3515 Q912P A913S L914P Y915L A916C ... tiling clone,   3515/3515
(100 %)
2 diff
(100.0 %id)
BI856086 breast, mammary adenocarcinoma, cell line ATXN2L.c 970 to 1821 1 to 856       856/858
(99 %)
16 diff
(98.2 %id)
TI_57186571   ATXN2L.c 970 to 1821 54 to 909       856/858
(99 %)
16 diff
(98.2 %id)
BE615860 adenocarcinoma, Pancreas ATXN2L.c 1085 to 1934 1 to 870       863/969
(89 %)
56 diff
(94.3 %id)
BE254934 eye, retinoblastoma ATXN2L.c 1355 to 2001 1 to 641       641/642
(99 %)
10 diff
(98.5 %id)
AJ317971   ATXN2L.d 1 to 3787 1 to 3787 T745S P782T L1105F tiling clone, AAA Possibly primed on the genome, locally A rich (21/24 A in genome downstream of last aligned base) 3787/3787
(100 %)
8 diff
(99.8 %id)
NM_145714.1   ATXN2L.d 1 to 3787 1 to 3787 exact RefSeq, AAA Possibly primed on the genome, locally A rich (21/24 A in genome downstream of last aligned base) 3787/3787
(100 %)
2 diff
(100.0 %id)
BX092100 breast ATXN2L.d 2963 to 3673 1 to 711   tiling clone,   711/711
(100 %)
0 diff
(100 %id)
AJ317973   ATXN2L.e 1 to 3761 1 to 3761 T745S P782T tiling clone, AAA Possibly primed on the genome, locally A rich (21/24 A in genome downstream of last aligned base) 3761/3761
(100 %)
8 diff
(99.8 %id)
NM_148415.1   ATXN2L.e 1 to 3761 1 to 3761 exact RefSeq, AAA Possibly primed on the genome, locally A rich (21/24 A in genome downstream of last aligned base) 3761/3761
(100 %)
2 diff
(100.0 %id)
BC136584 Testicle, PCR rescued clones ATXN2L.e 4 to 3450 1 to 3447   tiling clone,   3447/3447
(100 %)
1 diff
(100.0 %id)
TI_1971555477   ATXN2L.e 2422 to 3450 1262 to 254       1009/1292
(78 %)
14 diff
(99.0 %id)
BM755797 Ascites, stomach ATXN2L.e 2759 to 3370 1 to 613       613/613
(100 %)
3 diff
(99.6 %id)
BM755810 Ascites, stomach ATXN2L.e 2759 to 3303 1 to 545       545/545
(100 %)
2 diff
(99.7 %id)
BM756598 Ascites, stomach ATXN2L.e 2759 to 3355 1 to 598       598/598
(100 %)
4 diff
(99.4 %id)
BM741714 Ascites, stomach ATXN2L.e 2759 to 3411 1 to 653       653/653
(100 %)
3 diff
(99.6 %id)
TI_149300458   ATXN2L.e 2810 to 3761 1019 to 83   AAA Possibly primed on the genome, locally A rich (21/24 A in genome downstream of last aligned base) 937/969
(96 %)
23 diff
(97.7 %id)
H45145 breast ATXN2L.e 3007 to 3433 1 to 441   fully sequenced,   441/441
(100 %)
14 diff
(96.9 %id)
TI_154041343   ATXN2L.e 3064 to 3761 774 to 80   AAA Possibly primed on the genome, locally A rich (21/24 A in genome downstream of last aligned base) 695/961
(72 %)
18 diff
(98.2 %id)
BM976440 lung, Primary Lung Cystic Fibrosis EpithelialCells ATXN2L.e 3082 to 3761 697 to 19   AAA Possibly primed on the genome, locally A rich (21/24 A in genome downstream of last aligned base) 679/679
(100 %)
2 diff
(99.8 %id)
BU685001 lung, Primary Lung Cystic Fibrosis EpithelialCells ATXN2L.e 3088 to 3756 686 to 19   AAA Possibly primed on the genome, locally A rich (21/24 A in genome downstream of last aligned base) 668/668
(100 %)
2 diff
(99.8 %id)
BQ017451 lung, Metastatic Chondrosarcoma ATXN2L.e 3094 to 3761 684 to 19   tiling clone, AAA Possibly primed on the genome, locally A rich (21/24 A in genome downstream of last aligned base) 666/668
(99 %)
2 diff
(99.8 %id)
BU619363 cell lines, Chondrosarcoma ATXN2L.e 3235 to 3761 549 to 19   AAA Possibly primed on the genome, locally A rich (21/24 A in genome downstream of last aligned base) 531/531
(100 %)
6 diff
(98.9 %id)
BU623640 cell lines, Enchondroma ATXN2L.e 3236 to 3761 545 to 19   AAA Possibly primed on the genome, locally A rich (21/24 A in genome downstream of last aligned base) 527/527
(100 %)
4 diff
(99.3 %id)
BG121457 adenocarcinoma, cell line, Liver ATXN2L.e 3258 to 3724 1 to 465   AAA   465/510
(91 %)
3 diff
(99.5 %id)
H45446 breast ATXN2L.e 3403 to 3716 315 to 1   fully sequenced,   315/315
(100 %)
3 diff
(99.1 %id)
BC082760 Lymph, lymphoma ATXN2L.f 1 to 3617 1 to 3617 exact tiling clone, available from MGC, AAA Possibly primed on the genome, locally A rich (21/24 A in genome downstream of last aligned base) 3617/3617
(100 %)
1 diff
(100.0 %id)
TI_2194645568   ATXN2L.f 2252 to 3344 1140 to 51     Submitted on the opposite strand 1090/1162
(93 %)
28 diff
(97.6 %id)
TI_2194643696   ATXN2L.f 2424 to 3344 989 to 60     Submitted on the opposite strand 930/1359
(68 %)
32 diff
(97.7 %id)
AA029963 uterus ATXN2L.f 2910 to 3147 1 to 239     Possibly primed on the genome, locally A rich (21/24 A in genome downstream of last aligned base) 239/246
(97 %)
6 diff
(97.6 %id)
AA310767   ATXN2L.f 2926 to 3256 1 to 333       333/333
(100 %)
2 diff
(99.4 %id)
AL137587 testis ATXN2L.f 3031 to 3650 1 to 620   available from DKFZ, AAA Possibly primed on the genome, locally A rich (21/24 A in genome downstream of last aligned base) 620/620
(100 %)
0 diff
(100 %id)
AA323336 brain, cerebellum ATXN2L.f 3107 to 3269 1 to 163       163/163
(100 %)
0 diff
(100 %id)
AA029964 uterus ATXN2L.f 3303 to 3650 362 to 15   AAA Possibly primed on the genome, locally A rich (21/24 A in genome downstream of last aligned base) 348/348
(100 %)
0 diff
(100 %id)
AK289981 hippocampus ATXN2L.g 1 to 3782 1 to 3782 exact tiling clone,   3782/3782
(100 %)
1 diff
(100.0 %id)
DA320741 hippocampus ATXN2L.g 2 to 549 2 to 549   capped   548/548
(100 %)
0 diff
(100 %id)
DB287307 uterus ATXN2L.g 21 to 574 2 to 555   capped   554/554
(100 %)
0 diff
(100 %id)
AJ317974   ATXN2L.g 45 to 3782 1 to 3738 T689S P726T L1031F tiling clone, AAA Possibly primed on the genome, locally A rich (21/24 A in genome downstream of last aligned base) 3738/3738
(100 %)
8 diff
(99.8 %id)
NM_148416.1   ATXN2L.g 45 to 3782 1 to 3738 exact RefSeq, AAA Possibly primed on the genome, locally A rich (21/24 A in genome downstream of last aligned base) 3738/3738
(100 %)
2 diff
(100.0 %id)
TI_1971553677   ATXN2L.g 48 to 1181 66 to 1199     Submitted on the opposite strand 1134/1260
(90 %)
31 diff
(97.6 %id)
TI_2194643697   ATXN2L.g 48 to 1018 64 to 1037     Submitted on the opposite strand 974/1257
(77 %)
27 diff
(97.9 %id)
TI_2194645949   ATXN2L.g 48 to 1047 64 to 1074     Submitted on the opposite strand 1009/1352
(74 %)
23 diff
(98.3 %id)
BM148174 leukopheresis ATXN2L.g 130 to 431 1 to 302       302/302
(100 %)
1 diff
(99.7 %id)
AW593132 pooled ATXN2L.g 155 to 281 127 to 1       127/127
(100 %)
1 diff
(99.3 %id)
DB460597 testis ATXN2L.g 188 to 664 1 to 477       477/477
(100 %)
1 diff
(99.8 %id)
BQ057070 lymph, lymphoma, cell line ATXN2L.g 207 to 1046 1 to 846       846/1006
(84 %)
32 diff
(96.9 %id)
BQ058513 lymph, lymphoma, cell line ATXN2L.g 207 to 1104 1 to 910   AAA   908/1008
(90 %)
23 diff
(97.8 %id)
BQ061071 lymph, lymphoma, cell line ATXN2L.g 207 to 1044 1 to 839       839/966
(86 %)
10 diff
(99.0 %id)
BQ066205 lymph, lymphoma, cell line ATXN2L.g 207 to 1023 1 to 829       829/1033
(80 %)
27 diff
(97.4 %id)
BQ898990 lymph, lymphoma, cell line ATXN2L.g 207 to 1022 1 to 822       822/823
(99 %)
11 diff
(98.7 %id)
CN394687 embryonic stem cells, cell lines H1, H7, andH9 ATXN2L.g 218 to 897 10 to 689       680/689
(98 %)
6 diff
(99.2 %id)
CN394685 embryonic stem cells, cell lines H1, H7, andH9 ATXN2L.g 280 to 839 1 to 560       560/560
(100 %)
0 diff
(100 %id)
AI499567 moderately-differentiated endometrialadenocarcinoma, 3 pooled tumors, uterus ATXN2L.g 368 to 907 1 to 540     Submitted on the opposite strand 540/544
(99 %)
6 diff
(98.9 %id)
AI239982 pooled ATXN2L.g 369 to 947 1 to 579     Submitted on the opposite strand 579/579
(100 %)
2 diff
(99.7 %id)
AI243168 pooled ATXN2L.g 369 to 885 1 to 516     Submitted on the opposite strand 516/516
(100 %)
4 diff
(99.3 %id)
AI439594 B-cell, chronic lymphotic leukemia ATXN2L.g 369 to 828 1 to 460     Submitted on the opposite strand 460/460
(100 %)
1 diff
(99.8 %id)
AI693921 pooled ATXN2L.g 369 to 1133 1 to 764     Submitted on the opposite strand 764/765
(99 %)
13 diff
(98.4 %id)
AW166527 cervix ATXN2L.g 369 to 911 1 to 543     Submitted on the opposite strand 543/543
(100 %)
2 diff
(99.7 %id)
BE674857 B-cell, chronic lymphotic leukemia ATXN2L.g 369 to 1078 1 to 710     Submitted on the opposite strand 710/711
(99 %)
4 diff
(99.5 %id)
AW016067   ATXN2L.g 370 to 666 1 to 297     Submitted on the opposite strand 297/297
(100 %)
7 diff
(97.7 %id)
AW138543   ATXN2L.g 370 to 623 1 to 254     Submitted on the opposite strand 254/254
(100 %)
8 diff
(96.9 %id)
AW139247   ATXN2L.g 370 to 642 1 to 273     Submitted on the opposite strand 273/273
(100 %)
5 diff
(98.2 %id)
BF733001 fibrotheoma, ovary ATXN2L.g 378 to 722 1 to 346     Submitted on the opposite strand 346/346
(100 %)
3 diff
(99.2 %id)
AW468945 pooled ATXN2L.g 383 to 720 1 to 340     Submitted on the opposite strand 340/340
(100 %)
2 diff
(99.5 %id)
BG152737 fibrotheoma, ovary ATXN2L.g 383 to 487 1 to 105     Submitted on the opposite strand 105/118
(88 %)
10 diff
(91.6 %id)
AI379895 mixed (see below), Pooled human melanocyte, fetal heart, andpregnant uterus ATXN2L.g 387 to 1223 1 to 837     Submitted on the opposite strand 837/837
(100 %)
14 diff
(98.4 %id)
AI183803 lung ATXN2L.g 402 to 911 1 to 510     Submitted on the opposite strand 510/510
(100 %)
6 diff
(98.9 %id)
AI246237 mixed (see below), Pooled human melanocyte, fetal heart, andpregnant uterus ATXN2L.g 405 to 931 1 to 526     Submitted on the opposite strand 526/528
(99 %)
14 diff
(97.4 %id)
BU151344 eye, normal pigmented retinal epithelium ATXN2L.g 405 to 1162 1 to 766       766/970
(78 %)
16 diff
(98.4 %id)
AI654203 pooled germ cell tumors ATXN2L.g 419 to 1046 1 to 628     Submitted on the opposite strand 628/652
(96 %)
20 diff
(97.0 %id)
N24050 melanocyte ATXN2L.g 444 to 865 1 to 425     Submitted on the opposite strand 425/425
(100 %)
8 diff
(98.2 %id)
AA831794 germinal center B cell ATXN2L.g 445 to 733 1 to 288     Submitted on the opposite strand 288/288
(100 %)
11 diff
(96.2 %id)
N73088.
matches multiple genes
melanocyte ATXN2L.g 448 to 635 71 to 256     Submitted on the opposite strand, also hits gene chykoyby 186/256
(72 %)
7 diff
(97.3 %id)
AA489229 germinal center B cell ATXN2L.g 450 to 771 1 to 320     Submitted on the opposite strand 320/320
(100 %)
5 diff
(98.5 %id)
AA830097 germinal center B cell ATXN2L.g 464 to 784 1 to 319     Submitted on the opposite strand 319/319
(100 %)
6 diff
(98.2 %id)
AA810910 germinal center B cell ATXN2L.g 465 to 842 1 to 376     Submitted on the opposite strand 376/376
(100 %)
5 diff
(98.7 %id)
BF745406 breast ATXN2L.g 523 to 725 206 to 2     Submitted on the opposite strand 205/229
(89 %)
3 diff
(98.7 %id)
BM476061 eye, retinoblastoma ATXN2L.g 531 to 1420 24 to 920       897/1031
(87 %)
24 diff
(97.7 %id)
AW170623 cervix, tumor ATXN2L.g 544 to 1046 1 to 503     Submitted on the opposite strand 503/536
(93 %)
19 diff
(96.5 %id)
CN394695 embryonic stem cells, embryoid bodiesderived from H1, H7 and H9 cells ATXN2L.g 557 to 1093 1 to 537       537/537
(100 %)
1 diff
(99.9 %id)
BG024846 lymph, lymphoma, cell line ATXN2L.g 561 to 1231 94 to 765       672/1095
(61 %)
20 diff
(98.2 %id)
AA905629 pooled ATXN2L.g 581 to 878 1 to 297     Submitted on the opposite strand 297/297
(100 %)
3 diff
(99.0 %id)
AA381328   ATXN2L.g 630 to 903 1 to 274       274/274
(100 %)
1 diff
(99.7 %id)
BE273553 Kidney, renal cell adenocarcinoma ATXN2L.g 630 to 1255 1 to 627       627/627
(100 %)
17 diff
(97.3 %id)
DB223067 trachea ATXN2L.g 678 to 1242 2 to 566   capped   565/565
(100 %)
0 diff
(100 %id)
BF904450 marrow ATXN2L.g 683 to 891 383 to 175     Submitted on the opposite strand 209/383
(54 %)
1 diff
(99.8 %id)
BF798065 lymph, lymphoma, cell line ATXN2L.g 755 to 1392 26 to 684       659/726
(90 %)
33 diff
(95.5 %id)
T19149   ATXN2L.g 764 to 1157 1 to 398       398/402
(99 %)
13 diff
(96.8 %id)
BQ900976 sympathetic trunk ATXN2L.g 772 to 1667 1 to 911       907/936
(96 %)
35 diff
(96.3 %id)
DA803797 brain ATXN2L.g 777 to 1343 2 to 568   capped   567/567
(100 %)
0 diff
(100 %id)
CX759188 Blastocyst, pluripotent cell line derived fromblastocyst inner cell mass ATXN2L.g 798 to 1534 1 to 730     Submitted on the opposite strand 730/841
(86 %)
12 diff
(98.6 %id)
CN394684 embryonic stem cells, cell lines H1, H7, andH9 ATXN2L.g 817 to 1402 1 to 586       586/586
(100 %)
0 diff
(100 %id)
CR742278 pooled ATXN2L.g 826 to 1129 304 to 1     Submitted on the opposite strand 304/304
(100 %)
1 diff
(99.7 %id)
H03566 placenta ATXN2L.g 831 to 1268 454 to 1     Submitted on the opposite strand 454/463
(98 %)
23 diff
(95.1 %id)
DR760072 embryonic stem ATXN2L.g 836 to 1599 1 to 764       764/764
(100 %)
1 diff
(99.9 %id)
AL045221 testis ATXN2L.g 839 to 1331 1 to 493       493/493
(100 %)
0 diff
(100 %id)
BU177259 melanotic melanoma, skin ATXN2L.g 840 to 1701 1 to 870       870/876
(99 %)
14 diff
(98.5 %id)
BQ954354 sciatic nerve ATXN2L.g 847 to 1705 871 to 1     Submitted on the opposite strand 871/880
(98 %)
26 diff
(97.1 %id)
BQ720005 sympathetic trunk ATXN2L.g 856 to 1600 12 to 763       752/935
(80 %)
26 diff
(97.3 %id)
CA431996 cell lines, Chondrosarcoma ATXN2L.g 874 to 1582 731 to 24       708/731
(96 %)
5 diff
(99.4 %id)
BU101709   ATXN2L.g 875 to 1533 1 to 658       658/664
(99 %)
3 diff
(99.6 %id)
BE085577 breast ATXN2L.g 897 to 1110 1 to 215       215/229
(93 %)
7 diff
(97.0 %id)
BM542977 embryonal carcinoma, cell line, testis ATXN2L.g 913 to 1735 1 to 827       827/1025
(80 %)
14 diff
(98.7 %id)
CR983408 T-Lymphocytes ATXN2L.g 915 to 1586 1 to 674       674/674
(100 %)
3 diff
(99.6 %id)
BG960197 colon ATXN2L.g 916 to 1286 1 to 371       371/371
(100 %)
6 diff
(98.4 %id)
BG180875 adenocarcinoma, cell line, Prostate ATXN2L.g 917 to 1647 1 to 711       713/915
(77 %)
35 diff
(96.2 %id)
BM468668 leiomyosarcoma, uterus ATXN2L.g 932 to 1868 1 to 948       948/1009
(93 %)
20 diff
(98.1 %id)
AA625262 mixed (see below), Pooled human melanocyte, fetal heart, andpregnant uterus ATXN2L.g 966 to 1420 455 to 1     Submitted on the opposite strand 455/455
(100 %)
3 diff
(99.4 %id)
AW890234 nervous_tumor ATXN2L.g 969 to 1156 26 to 212       187/220
(85 %)
17 diff
(92.3 %id)
EH350246   ATXN2L.g 990 to 1054 1 to 65       65/65
(100 %)
1 diff
(98.5 %id)
BG480398 choriocarcinoma, placenta ATXN2L.g 994 to 1548 554 to 1     Submitted on the opposite strand 554/554
(100 %)
2 diff
(99.7 %id)
CR976507 T-Lymphocytes ATXN2L.g 1005 to 1660 1 to 657       657/657
(100 %)
2 diff
(99.7 %id)
BF593595 pooled germ cell tumors ATXN2L.g 1032 to 1422 391 to 1       391/397
(98 %)
11 diff
(97.3 %id)
DA268042 caudate nucleus ATXN2L.g 1037 to 1606 2 to 571   capped   570/570
(100 %)
1 diff
(99.9 %id)
TI_1971555487   ATXN2L.g 1057 to 1931 878 to 9       870/920
(94 %)
24 diff
(97.4 %id)
BQ339437 nervous_normal ATXN2L.g 1064 to 1355 298 to 1       298/302
(98 %)
13 diff
(95.7 %id)
BQ641689 eye, normal pigmented retinal epithelium ATXN2L.g 1069 to 1799 1 to 737       734/970
(75 %)
15 diff
(98.5 %id)
AL602400 human skeletal muscle ATXN2L.g 1083 to 1334 1 to 251       251/251
(100 %)
2 diff
(99.3 %id)
BF766572 colon_est ATXN2L.g 1089 to 1246 12 to 169       158/169
(93 %)
6 diff
(96.5 %id)
AA323163 brain, cerebellum ATXN2L.g 1116 to 1412 1 to 297       297/297
(100 %)
0 diff
(100 %id)
BG988125 head_neck ATXN2L.g 1118 to 1599 181 to 662       480/666
(72 %)
22 diff
(96.7 %id)
BM801411 duodenal adenocarcinoma, cell line, small intestine ATXN2L.g 1121 to 1533 20 to 432       413/1197
(34 %)
14 diff
(98.9 %id)
BE269967 Burkitt lymphoma, lymph ATXN2L.g 1137 to 1568 1 to 431       431/609
(70 %)
8 diff
(98.7 %id)
TI_1971555481   ATXN2L.g 1140 to 1800 9 to 669       661/1307
(50 %)
16 diff
(98.8 %id)
BU101710   ATXN2L.g 1144 to 1605 462 to 1       462/465
(99 %)
1 diff
(99.8 %id)
BF894551 marrow ATXN2L.g 1161 to 1554 1 to 398       398/398
(100 %)
8 diff
(98.0 %id)
BG819063 anaplastic oligodendroglioma with 1p/19qloss, brain ATXN2L.g 1164 to 1761 1 to 595       595/595
(100 %)
9 diff
(98.5 %id)
CN394677 embryonic stem cells, cell lines H1, H7, andH9 ATXN2L.g 1222 to 1562 1 to 341       341/341
(100 %)
1 diff
(99.8 %id)
BG980324 colon_normal ATXN2L.g 1224 to 1552 330 to 2       329/330
(99 %)
3 diff
(99.1 %id)
BE273701 Kidney, renal cell adenocarcinoma ATXN2L.g 1244 to 1800 72 to 657       588/716
(82 %)
38 diff
(94.7 %id)
BG914028 anaplastic oligodendroglioma with 1p/19qloss, brain ATXN2L.g 1283 to 1671 1 to 391       390/392
(99 %)
35 diff
(91.1 %id)
BE926250 breast_normal ATXN2L.g 1297 to 1596 310 to 10       301/327
(92 %)
3 diff
(99.1 %id)
BE926282 breast_normal ATXN2L.g 1297 to 1604 325 to 18       308/342
(90 %)
2 diff
(99.5 %id)
AW505144 lymph ATXN2L.g 1343 to 1684 1 to 342       342/342
(100 %)
5 diff
(98.6 %id)
TI_154161645   ATXN2L.g 1349 to 1871 71 to 593       523/717
(72 %)
27 diff
(96.3 %id)
CK431260 eye, lacrimal gland ATXN2L.g 1366 to 2009 1 to 644       644/644
(100 %)
1 diff
(99.9 %id)
BE538348 cervix ATXN2L.g 1418 to 2067 1 to 654       654/654
(100 %)
27 diff
(95.9 %id)
BG764274 melanotic melanoma, high MDR (cell line), skin ATXN2L.g 1418 to 2355 1 to 934       934/935
(99 %)
24 diff
(97.5 %id)
BG764208 melanotic melanoma, high MDR (cell line), skin ATXN2L.g 1418 to 2101 1 to 700       700/1136
(61 %)
59 diff
(94.9 %id)
BF312653 brain, neuroblastoma ATXN2L.g 1463 to 2102 1 to 635       635/635
(100 %)
7 diff
(98.9 %id)
BU192724 eye, retinoblastoma ATXN2L.g 1495 to 2312 12 to 850       838/898
(93 %)
44 diff
(95.2 %id)
AI904390 breast ATXN2L.g 1502 to 1739 14 to 251       238/251
(94 %)
13 diff
(94.9 %id)
CK000969 mixed ATXN2L.g 1520 to 2279 1 to 756       756/759
(99 %)
10 diff
(98.7 %id)
CA396242 eye, RPE/choroid ATXN2L.g 1525 to 2067 1 to 543       543/543
(100 %)
0 diff
(100 %id)
BX465172 neuroblastoma ATXN2L.g 1535 to 2688 7 to 1163       1157/1163
(99 %)
20 diff
(98.3 %id)
TI_154110604   ATXN2L.g 1549 to 2356 923 to 119       805/1052
(76 %)
5 diff
(99.6 %id)
BM470681 eye, retinoblastoma ATXN2L.g 1556 to 2371 35 to 861       827/1044
(79 %)
21 diff
(98.0 %id)
BQ367668 placenta_normal ATXN2L.g 1570 to 1882 56 to 362       307/362
(84 %)
6 diff
(98.4 %id)
BU181189 embryonal carcinoma, cell line, testis ATXN2L.g 1574 to 2490 1 to 926       926/926
(100 %)
13 diff
(98.6 %id)
BM069690 Islets of Langerhans, Pancreas ATXN2L.g 1577 to 2153 1 to 577       577/577
(100 %)
0 diff
(100 %id)
BM806356 leiomyosarcoma, uterus ATXN2L.g 1588 to 2639 1 to 1060       1058/1082
(97 %)
27 diff
(97.6 %id)
AI904350 breast ATXN2L.g 1596 to 1711 1 to 116       116/117
(99 %)
1 diff
(99.2 %id)
AI904357 breast ATXN2L.g 1596 to 1711 1 to 116       116/117
(99 %)
1 diff
(99.2 %id)
CR992099 T-Lymphocytes ATXN2L.g 1608 to 2456 1 to 849       849/871
(97 %)
3 diff
(99.7 %id)
BG177019 lymph, lymphoma, cell line ATXN2L.g 1613 to 2364 1 to 749       749/937
(79 %)
14 diff
(98.6 %id)
TI_1971558549   ATXN2L.g 1648 to 2782 1143 to 12       1134/1257
(90 %)
11 diff
(99.2 %id)
CN394688 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 ATXN2L.g 1654 to 2072 1 to 419       419/419
(100 %)
0 diff
(100 %id)
BM456155 lymph, lymphoma, cell line ATXN2L.g 1658 to 2456 1 to 808       808/837
(96 %)
14 diff
(98.4 %id)
CN394678 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 ATXN2L.g 1676 to 2237 575 to 13     Submitted on the opposite strand 563/575
(97 %)
1 diff
(99.9 %id)
BE314750 brain, neuroblastoma ATXN2L.g 1679 to 2327 47 to 693       647/693
(93 %)
13 diff
(98.2 %id)
BU102029   ATXN2L.g 1684 to 2359 1 to 677       677/677
(100 %)
1 diff
(99.9 %id)
BG998854 head_neck ATXN2L.g 1705 to 1991 1 to 287       287/287
(100 %)
3 diff
(99.0 %id)
AI565533 anaplastic oligodendroglioma, brain ATXN2L.g 1710 to 2046 379 to 43   AAA   337/348
(96 %)
0 diff
(100 %id)
BM468164 leiomyosarcoma, uterus ATXN2L.g 1716 to 2645 37 to 970       934/1101
(84 %)
16 diff
(98.6 %id)
BX333653 Neuroblastoma Cot 25-normalized ATXN2L.g 1728 to 2457 740 to 1     Submitted on the opposite strand 740/740
(100 %)
23 diff
(96.9 %id)
BG992506 head_neck ATXN2L.g 1735 to 2298 570 to 11       560/570
(98 %)
4 diff
(99.3 %id)
BM549871 astrocytoma grade IV, cell line, brain ATXN2L.g 1756 to 2642 1 to 891       891/1014
(87 %)
9 diff
(99.2 %id)
BF343431 brain, glioblastoma with EGFR amplification ATXN2L.g 1760 to 2455 1 to 691       691/767
(90 %)
10 diff
(98.7 %id)
CD623952   ATXN2L.g 1762 to 2285 14 to 537       524/537
(97 %)
0 diff
(100 %id)
BQ182962 Chondrosarcoma, Left Pubic Bone ATXN2L.g 1768 to 2356 618 to 30   AAA   589/600
(98 %)
3 diff
(99.5 %id)
TI_1971559101   ATXN2L.g 1788 to 2864 1079 to 17       1068/1224
(87 %)
31 diff
(97.5 %id)
AI138353   ATXN2L.g 1788 to 2259 475 to 4       472/475
(99 %)
0 diff
(100 %id)
BG912047 anaplastic oligodendroglioma with 1p/19qloss, brain ATXN2L.g 1792 to 2585 1 to 794       794/794
(100 %)
5 diff
(99.4 %id)
BQ308842 breast ATXN2L.g 1798 to 2059 1 to 262       262/263
(99 %)
10 diff
(96.2 %id)
AW673573 cervix ATXN2L.g 1799 to 2375 1 to 577     Possibly primed on the genome, locally A rich (21/24 A in genome downstream of last aligned base) 577/577
(100 %)
3 diff
(99.5 %id)
AW673582 cervix ATXN2L.g 1799 to 2369 1 to 571     Possibly primed on the genome, locally A rich (21/24 A in genome downstream of last aligned base) 571/571
(100 %)
7 diff
(98.8 %id)
BQ308271 breast ATXN2L.g 1803 to 2087 23 to 308       286/311
(91 %)
10 diff
(96.8 %id)
BE397036 Burkitt lymphoma, lymph ATXN2L.g 1805 to 2333 1 to 538       538/538
(100 %)
12 diff
(97.8 %id)
BQ053420 blood, natural killer cells, cell line ATXN2L.g 1805 to 2646 1 to 853       853/1104
(77 %)
21 diff
(98.1 %id)
BE513821 Burkitt lymphoma, lymph ATXN2L.g 1807 to 2455 1 to 649       649/680
(95 %)
1 diff
(99.9 %id)
BE543482 cervical carcinoma cell line, cervix ATXN2L.g 1813 to 2455 1 to 638       638/756
(84 %)
8 diff
(99.0 %id)
BF844818 head_neck ATXN2L.g 1835 to 2335 504 to 3     Submitted on the opposite strand 502/516
(97 %)
17 diff
(96.8 %id)
W22665 eye, retina ATXN2L.g 1872 to 2378 547 to 36       512/700
(73 %)
23 diff
(96.8 %id)
TI_151770715   ATXN2L.g 1873 to 2458 120 to 706   AAA   587/1248
(47 %)
11 diff
(99.2 %id)
BF828920 head_normal ATXN2L.g 1897 to 2453 604 to 52     Submitted on the opposite strand 553/606
(91 %)
7 diff
(98.9 %id)
DA337191 hippocampus ATXN2L.g 1898 to 2478 2 to 582   capped   581/581
(100 %)
2 diff
(99.7 %id)
CN394699 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 ATXN2L.g 1909 to 2619 9 to 719       711/719
(98 %)
6 diff
(99.2 %id)
BI260692 cervical carcinoma cell line, cervix ATXN2L.g 1915 to 2730 1 to 815       815/815
(100 %)
12 diff
(98.6 %id)
CD300152 testis ATXN2L.g 1915 to 2769 28 to 888       861/890
(96 %)
19 diff
(97.9 %id)
CN394700 embryonic stem cells, DMSO-treated H9 cellline ATXN2L.g 1929 to 2665 1 to 737       737/737
(100 %)
0 diff
(100 %id)
BU164073 large cell carcinoma, lung ATXN2L.g 1929 to 2823 1 to 896       896/897
(99 %)
12 diff
(98.7 %id)
CN394680 embryonic stem cells, embryoid bodiesderived from H1, H7 and H9 cells ATXN2L.g 1943 to 2507 25 to 589       565/589
(95 %)
6 diff
(99.0 %id)
BY799658 eye ATXN2L.g 1965 to 2578 1 to 613       613/613
(100 %)
1 diff
(99.9 %id)
BG030932 breast, mammary adenocarcinoma, cell line ATXN2L.g 1965 to 2762 1 to 787       787/852
(92 %)
27 diff
(96.9 %id)
DR159312 human embryonic stem cells differentiated toan early endodermal cell type ATXN2L.g 1997 to 2688 704 to 13     Submitted on the opposite strand 692/704
(98 %)
0 diff
(100 %id)
BU102030   ATXN2L.g 2006 to 2621 620 to 4       617/621
(99 %)
0 diff
(100 %id)
BF947866 nervous_normal ATXN2L.g 2040 to 2350 19 to 328       310/328
(94 %)
8 diff
(97.6 %id)
CN394697 embryonic stem cells, DMSO-treated H9 cellline ATXN2L.g 2043 to 2645 1 to 603       603/603
(100 %)
3 diff
(99.6 %id)
BI003246 head_normal ATXN2L.g 2044 to 2285 1 to 242       242/242
(100 %)
12 diff
(95.1 %id)
BF947859 nervous_normal ATXN2L.g 2053 to 2339 20 to 301       282/301
(93 %)
13 diff
(95.7 %id)
BF038727 adenocarcinoma, ovary ATXN2L.g 2054 to 2781 1 to 723       723/1105
(65 %)
16 diff
(98.6 %id)
BF847023 lung_normal ATXN2L.g 2056 to 2308 1 to 252       252/252
(100 %)
10 diff
(96.1 %id)
AI247133 adenocarcinoma, Pancreas ATXN2L.g 2071 to 2344 1 to 274     Submitted on the opposite strand 274/274
(100 %)
5 diff
(98.2 %id)
BF801074 colon_ins ATXN2L.g 2076 to 2364 21 to 308       288/313
(92 %)
7 diff
(97.8 %id)
BI050142 placenta_normal ATXN2L.g 2082 to 2380 321 to 13       309/328
(94 %)
22 diff
(93.3 %id)
BG955575 colon ATXN2L.g 2085 to 2519 1 to 437       437/437
(100 %)
4 diff
(99.1 %id)
CU451181 epidermis ATXN2L.g 2091 to 2573 501 to 20     Submitted on the opposite strand 482/503
(95 %)
4 diff
(99.3 %id)
BF880140 lung_tumor ATXN2L.g 2099 to 2489 1 to 391       391/391
(100 %)
6 diff
(98.5 %id)
BG986177 epid_tumor ATXN2L.g 2103 to 2423 13 to 330       318/330
(96 %)
6 diff
(98.2 %id)
BF880135 lung_tumor ATXN2L.g 2107 to 2489 12 to 394       383/394
(97 %)
6 diff
(98.5 %id)
BF839388 head_neck ATXN2L.g 2120 to 2410 1 to 291       291/291
(100 %)
5 diff
(98.3 %id)
BQ335680 marrow ATXN2L.g 2120 to 2295 1 to 179       179/193
(92 %)
15 diff
(92.3 %id)
CN394694 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 ATXN2L.g 2126 to 2315 1 to 190       190/190
(100 %)
0 diff
(100 %id)
AW352248 head_neck ATXN2L.g 2130 to 2594 1 to 469       469/471
(99 %)
19 diff
(96.0 %id)
CN394681 embryonic stem cells, cell lines H1, H7, andH9 ATXN2L.g 2135 to 2897 1 to 762       762/763
(99 %)
1 diff
(99.9 %id)
BI009561 kidney_tumor ATXN2L.g 2136 to 2355 224 to 2       223/224
(99 %)
5 diff
(97.8 %id)
BI334687 cervical carcinoma cell line, cervix ATXN2L.g 2137 to 3019 1 to 884       879/975
(90 %)
25 diff
(97.5 %id)
BM909577 lymph, lymphoma, cell line ATXN2L.g 2138 to 3038 1 to 908       908/1070
(84 %)
14 diff
(98.7 %id)
CR978352 T-Lymphocytes ATXN2L.g 2138 to 3018 1 to 878       878/886
(99 %)
9 diff
(99.0 %id)
AW806639 stomach ATXN2L.g 2148 to 2642 495 to 1       495/495
(100 %)
6 diff
(98.8 %id)
AW844992 colon ATXN2L.g 2157 to 2365 212 to 4       209/213
(98 %)
0 diff
(100 %id)
BQ315604 colon ATXN2L.g 2157 to 2358 202 to 1       202/203
(99 %)
0 diff
(100 %id)
AW844982 colon ATXN2L.g 2158 to 2470 5 to 317       313/317
(98 %)
0 diff
(100 %id)
AW806736 stomach ATXN2L.g 2168 to 2366 14 to 213       200/213
(93 %)
6 diff
(97.2 %id)
BQ300244 bladder_tumor ATXN2L.g 2168 to 2579 19 to 428       410/428
(95 %)
10 diff
(97.7 %id)
BE140437 head_neck ATXN2L.g 2174 to 2638 1 to 461       461/464
(99 %)
16 diff
(96.6 %id)
BE140436 head_neck ATXN2L.g 2176 to 2346 1 to 167       167/167
(100 %)
7 diff
(95.9 %id)
CN394686 embryonic stem cells, cell lines H1, H7, andH9 ATXN2L.g 2176 to 2714 1 to 539       539/539
(100 %)
0 diff
(100 %id)
CN394696 embryonic stem cells, DMSO-treated H9 cellline ATXN2L.g 2183 to 2733 1 to 553       553/553
(100 %)
2 diff
(99.7 %id)
BQ223699 embryonal carcinoma, cell line, testis ATXN2L.g 2186 to 3054 1 to 875       875/880
(99 %)
9 diff
(99.0 %id)
BQ300224 bladder_tumor ATXN2L.g 2188 to 2579 7 to 397       391/397
(98 %)
15 diff
(96.3 %id)
CX788661 human embryonic stem cells ATXN2L.g 2194 to 2932 1 to 739       739/739
(100 %)
1 diff
(99.9 %id)
BG259633 embryonal carcinoma, cell line, testis ATXN2L.g 2201 to 3015 1 to 806       806/890
(90 %)
25 diff
(97.2 %id)
DA814099   ATXN2L.g 2201 to 2758 2 to 559   capped   558/558
(100 %)
0 diff
(100 %id)
BF946272 nervous_normal ATXN2L.g 2207 to 2563 372 to 17       356/381
(93 %)
1 diff
(99.8 %id)
BF345181 anaplastic oligodendroglioma with 1p/19qloss, brain ATXN2L.g 2209 to 2930 8 to 728       718/859
(83 %)
18 diff
(98.0 %id)
BG389766 embryonal carcinoma, cell line, testis ATXN2L.g 2222 to 2955 1 to 735       736/799
(92 %)
21 diff
(97.4 %id)
AW373269 breast ATXN2L.g 2223 to 2564 1 to 342       342/342
(100 %)
0 diff
(100 %id)
AW581472 pnet ATXN2L.g 2223 to 2564 1 to 342       342/342
(100 %)
0 diff
(100 %id)
AW608627 pnet ATXN2L.g 2223 to 2564 1 to 342       342/342
(100 %)
0 diff
(100 %id)
BM759537 Ascites, stomach ATXN2L.g 2237 to 2877 1 to 642       642/642
(100 %)
2 diff
(99.7 %id)
DA126342 cerebellum ATXN2L.g 2238 to 2863 2 to 627   capped   626/626
(100 %)
2 diff
(99.7 %id)
BM541819 leiomyosarcoma, uterus ATXN2L.g 2238 to 3171 1 to 938       938/1031
(90 %)
14 diff
(98.7 %id)
BF918531 nervous_tumor ATXN2L.g 2239 to 2615 385 to 1     Submitted on the opposite strand 385/393
(97 %)
9 diff
(97.8 %id)
CA455370 adenocarcinoma, cell line, breast ATXN2L.g 2239 to 3037 1 to 803       803/871
(92 %)
7 diff
(99.2 %id)
DA181898 amygdala ATXN2L.g 2241 to 2795 2 to 556   capped   555/555
(100 %)
0 diff
(100 %id)
BE785133 large cell carcinoma, lung ATXN2L.g 2247 to 2916 1 to 679       676/944
(71 %)
12 diff
(98.8 %id)
BF850984 lung_normal ATXN2L.g 2261 to 2586 337 to 13     Submitted on the opposite strand 325/339
(95 %)
6 diff
(98.3 %id)
CN394692 embryonic stem cells, embryoid bodiesderived from H1, H7 and H9 cells ATXN2L.g 2263 to 2945 1 to 683       683/683
(100 %)
4 diff
(99.5 %id)
BU732789 eye, optic nerve ATXN2L.g 2264 to 2791 613 to 86   AAA   528/528
(100 %)
2 diff
(99.7 %id)
BG422464 Kidney, renal cell adenocarcinoma ATXN2L.g 2280 to 3022 1 to 728       728/801
(90 %)
27 diff
(96.7 %id)
CA424559 cell lines, Chondrosarcoma ATXN2L.g 2280 to 2802 547 to 26   AAA   522/528
(98 %)
9 diff
(98.3 %id)
AW378458 head_neck ATXN2L.g 2299 to 2778 1 to 478       478/478
(100 %)
11 diff
(97.7 %id)
DA382834 thalamus ATXN2L.g 2309 to 2937 2 to 630   capped   629/629
(100 %)
1 diff
(99.9 %id)
AI057510 liver and spleen ATXN2L.g 2322 to 2741 429 to 10       420/429
(97 %)
0 diff
(100 %id)
CN394691 embryonic stem cells, cell lines H1, H7, andH9 ATXN2L.g 2331 to 2940 14 to 622       609/622
(97 %)
6 diff
(99.1 %id)
CV808676 Blastocyst, pluripotent cell line derived fromblastocyst inner cell mass ATXN2L.g 2343 to 3048 37 to 748       709/750
(94 %)
22 diff
(97.1 %id)
BQ220071 large cell carcinoma, lung ATXN2L.g 2356 to 3108 1 to 757       757/904
(83 %)
20 diff
(97.8 %id)
BF797724 lymph, lymphoma, cell line ATXN2L.g 2361 to 3057 1 to 711       708/772
(91 %)
23 diff
(97.1 %id)
BQ069069 brain, neuroblastoma, cell line ATXN2L.g 2361 to 3171 1 to 824       824/999
(82 %)
7 diff
(99.3 %id)
CD623953   ATXN2L.g 2381 to 2756 377 to 1       377/377
(100 %)
1 diff
(99.8 %id)
CR996967 T-Lymphocytes ATXN2L.g 2384 to 3182 1 to 798       798/809
(98 %)
2 diff
(99.8 %id)
BF925188 nervous_tumor ATXN2L.g 2395 to 2813 446 to 27     Submitted on the opposite strand 420/459
(91 %)
6 diff
(98.7 %id)
CF146735 CNCAP(3)T-225 cell line, Prostate ATXN2L.g 2406 to 3108 8 to 709       702/715
(98 %)
8 diff
(98.9 %id)
CF122884 CNCAP(3)T-225 cell line, Prostate ATXN2L.g 2406 to 3011 8 to 613       606/613
(98 %)
6 diff
(99.1 %id)
TI_154179248   ATXN2L.g 2406 to 3209 69 to 870       802/804
(99 %)
9 diff
(98.9 %id)
TI_154182604   ATXN2L.g 2406 to 3197 69 to 856       788/862
(91 %)
8 diff
(99.1 %id)
BE763070 nervous_tumor ATXN2L.g 2414 to 2720 12 to 318       307/318
(96 %)
6 diff
(98.2 %id)
CX868369 embryonic stem ATXN2L.g 2416 to 3017 1 to 602       602/602
(100 %)
0 diff
(100 %id)
BU168258 epithelioid carcinoma, Pancreas ATXN2L.g 2420 to 3240 1 to 824       824/842
(97 %)
13 diff
(98.5 %id)
CN394676 embryonic stem cells, embryoid bodiesderived from H1, H7 and H9 cells ATXN2L.g 2426 to 3123 1 to 698       698/698
(100 %)
1 diff
(99.9 %id)
BM018603 astrocytoma grade IV, cell line, brain ATXN2L.g 2433 to 3140 1 to 708       708/708
(100 %)
7 diff
(99.1 %id)
AW845101 colon ATXN2L.g 2434 to 2758 327 to 3       325/327
(99 %)
0 diff
(100 %id)
BG014808 placenta_normal ATXN2L.g 2434 to 2795 365 to 3       363/372
(97 %)
13 diff
(96.6 %id)
TI_59389267   ATXN2L.g 2434 to 3140 108 to 814       707/707
(100 %)
6 diff
(99.2 %id)
BI019075 marrow ATXN2L.g 2435 to 2792 5 to 362       358/362
(98 %)
10 diff
(97.3 %id)
BG013939 placenta_normal ATXN2L.g 2441 to 2792 15 to 366       352/366
(96 %)
6 diff
(98.4 %id)
BG013941 placenta_normal ATXN2L.g 2444 to 2792 1 to 349       349/349
(100 %)
0 diff
(100 %id)
BG014068 placenta_normal ATXN2L.g 2444 to 2768 1 to 325       325/326
(99 %)
4 diff
(98.8 %id)
BI049508 placenta_normal ATXN2L.g 2444 to 2807 1 to 364       364/367
(99 %)
6 diff
(98.4 %id)
BQ335571 marrow ATXN2L.g 2444 to 2806 364 to 1       364/364
(100 %)
7 diff
(98.1 %id)
CX865928 embryonic stem ATXN2L.g 2445 to 3099 1 to 655       655/655
(100 %)
0 diff
(100 %id)
BG945692 bladder_tumor ATXN2L.g 2455 to 2766 16 to 318       303/349
(86 %)
15 diff
(95.8 %id)
BG012144 placenta_normal ATXN2L.g 2456 to 2781 331 to 3       329/331
(99 %)
3 diff
(99.1 %id)
BI010581 lung_normal ATXN2L.g 2456 to 2781 331 to 3       329/331
(99 %)
3 diff
(99.1 %id)
BM017450 astrocytoma grade IV, cell line, brain ATXN2L.g 2456 to 3155 21 to 715       695/723
(96 %)
19 diff
(97.4 %id)
TI_59387950   ATXN2L.g 2456 to 3155 151 to 845       695/722
(96 %)
19 diff
(97.4 %id)
BG995103 head_neck ATXN2L.g 2457 to 2623 165 to 3       163/177
(92 %)
10 diff
(94.4 %id)
BF737645 bladder_tumor ATXN2L.g 2462 to 2813 20 to 369       350/371
(94 %)
11 diff
(97.1 %id)
BF737646 bladder_tumor ATXN2L.g 2462 to 2769 58 to 362       305/375
(81 %)
14 diff
(96.3 %id)
BF985125 placenta_normal ATXN2L.g 2463 to 2873 30 to 440       411/444
(92 %)
17 diff
(96.2 %id)
BX457078 thymus ATXN2L.g 2474 to 3156 1 to 683       683/876
(77 %)
6 diff
(99.4 %id)
CN394698 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 ATXN2L.g 2480 to 2826 8 to 354       347/354
(98 %)
13 diff
(96.4 %id)
BG005736 placenta_normal ATXN2L.g 2490 to 2822 336 to 2       335/337
(99 %)
6 diff
(98.3 %id)
BF738479 bladder_tumor ATXN2L.g 2494 to 2808 44 to 351       308/351
(87 %)
20 diff
(94.4 %id)
BF959731 nervous_normal ATXN2L.g 2495 to 2678 1 to 185       185/185
(100 %)
6 diff
(96.8 %id)
CN394690 embryonic stem cells, DMSO-treated H9 cellline ATXN2L.g 2502 to 3138 639 to 3     Submitted on the opposite strand 637/639
(99 %)
0 diff
(100 %id)
BE268088 Burkitt lymphoma, lymph ATXN2L.g 2507 to 2890 166 to 549       384/549
(69 %)
6 diff
(99.0 %id)
BQ883031 dorsal root ganglia ATXN2L.g 2530 to 3300 29 to 810       782/1002
(78 %)
35 diff
(96.6 %id)
BG914238 anaplastic oligodendroglioma with 1p/19qloss, brain ATXN2L.g 2533 to 3032 1 to 498       498/498
(100 %)
4 diff
(99.2 %id)
BG945684 bladder_tumor ATXN2L.g 2535 to 2773 261 to 7       255/262
(97 %)
17 diff
(93.6 %id)
BQ431100 embryonal carcinoma, cell line, testis ATXN2L.g 2554 to 3299 38 to 789       752/847
(88 %)
22 diff
(97.5 %id)
CV361696 marrow ATXN2L.g 2559 to 2754 192 to 5     Submitted on the opposite strand 188/192
(97 %)
4 diff
(98.0 %id)
CT004756 T-Lymphocytes ATXN2L.g 2574 to 3226 1 to 655       655/655
(100 %)
2 diff
(99.7 %id)
BI086598 cervix ATXN2L.g 2591 to 3140 4 to 555       552/557
(99 %)
10 diff
(98.3 %id)
CX760648 Blastocyst, pluripotent cell line derived fromblastocyst inner cell mass ATXN2L.g 2603 to 3323 1 to 716     Submitted on the opposite strand 716/718
(99 %)
18 diff
(97.5 %id)
TI_154159731   ATXN2L.g 2621 to 3107 82 to 571       487/494
(98 %)
6 diff
(98.8 %id)
CR974660 T-Lymphocytes ATXN2L.g 2622 to 3218 1 to 598       598/602
(99 %)
3 diff
(99.6 %id)
AW119168 pooled ATXN2L.g 2643 to 2895 253 to 1       253/307
(82 %)
17 diff
(94.5 %id)
CN394693 embryonic stem cells, DMSO-treated H9 cellline ATXN2L.g 2671 to 2929 1 to 259       259/259
(100 %)
0 diff
(100 %id)
BM795330 Ascites, stomach ATXN2L.g 2671 to 3150 1 to 480       480/480
(100 %)
6 diff
(98.8 %id)
TI_1971555485   ATXN2L.g 2690 to 3088 415 to 18       395/628
(62 %)
9 diff
(98.6 %id)
BE395359 endometrium, adenocarcinoma cell line, uterus ATXN2L.g 2696 to 3350 1 to 652       652/674
(96 %)
17 diff
(97.5 %id)
CD623951   ATXN2L.g 2701 to 3107 22 to 430       406/453
(89 %)
9 diff
(98.1 %id)
CN394689 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 ATXN2L.g 2704 to 3156 10 to 462       453/462
(98 %)
9 diff
(98.1 %id)
BM797547 Ascites, stomach ATXN2L.g 2730 to 3224 1 to 495       495/495
(100 %)
0 diff
(100 %id)
BE929193 placenta_normal ATXN2L.g 2796 to 2934 23 to 158       136/158
(86 %)
6 diff
(96.3 %id)
BM744078 Ascites, stomach ATXN2L.g 2803 to 2897 1 to 96       96/102
(94 %)
5 diff
(95.1 %id)
BM743620 Ascites, stomach ATXN2L.g 2803 to 3297 1 to 495       495/495
(100 %)
2 diff
(99.6 %id)
AW245497 lung, small cell carcinoma ATXN2L.g 2805 to 3250 10 to 455     Possibly primed on the genome, locally A rich (21/24 A in genome downstream of last aligned base) 446/456
(97 %)
8 diff
(98.3 %id)
BI224569 cervical carcinoma cell line, cervix ATXN2L.g 2806 to 3186 37 to 413       377/551
(68 %)
11 diff
(98.1 %id)
BI223139 cervical carcinoma cell line, cervix ATXN2L.g 2818 to 3141 1 to 324       324/324
(100 %)
0 diff
(100 %id)
BE264271 lung, small cell carcinoma ATXN2L.g 2824 to 3231 1 to 404       404/405
(99 %)
7 diff
(98.3 %id)
BG009401 placenta_normal ATXN2L.g 2905 to 3079 12 to 184       173/185
(93 %)
5 diff
(97.3 %id)
BU620735 cell lines, Chondrosarcoma ATXN2L.g 3280 to 3777 519 to 19   AAA Possibly primed on the genome, locally A rich (21/24 A in genome downstream of last aligned base) 501/501
(100 %)
4 diff
(99.3 %id)
AW245940 lung, small cell carcinoma ATXN2L.g 3339 to 3782 454 to 11   AAA Possibly primed on the genome, locally A rich (21/24 A in genome downstream of last aligned base) 444/444
(100 %)
0 diff
(100 %id)
CX868288 embryonic stem ATXN2L.g 3401 to 3772 404 to 33   AAA   372/377
(98 %)
0 diff
(100 %id)
AW731719 cervix ATXN2L.g 3411 to 3782 390 to 19   AAA Possibly primed on the genome, locally A rich (21/24 A in genome downstream of last aligned base) 372/372
(100 %)
1 diff
(99.8 %id)
AW731730 cervix ATXN2L.g 3411 to 3782 390 to 19   AAA Possibly primed on the genome, locally A rich (21/24 A in genome downstream of last aligned base) 372/372
(100 %)
1 diff
(99.8 %id)
CX165071 human embryonic stem cells differentiated toan early endodermal cell type ATXN2L.h 1 to 805 1 to 804   tiling clone,   804/804
(100 %)
1 diff
(99.9 %id)
T80387 whole brain ATXN2L.h 747 to 1120 1 to 370       370/378
(97 %)
30 diff
(92.1 %id)
T80390 whole brain ATXN2L.h 747 to 1060 1 to 311       311/311
(100 %)
9 diff
(97.2 %id)
BC010239 Brain, anaplastic oligodendroglioma with1p/19q loss ATXN2L.h 749 to 2886 1 to 2138   tiling clone, available from MGC, AAA Possibly primed on the genome, locally A rich (21/24 A in genome downstream of last aligned base) 2138/2138
(100 %)
0 diff
(100 %id)
T80392 whole brain ATXN2L.h 772 to 1009 1 to 235     Possibly primed on the genome, locally A rich (21/24 A in genome downstream of last aligned base) 235/235
(100 %)
7 diff
(97.1 %id)
AA312527   ATXN2L.h 1115 to 1492 1 to 378       378/378
(100 %)
0 diff
(100 %id)
BU429759 lymph ATXN2L.h 1126 to 1621 1 to 496       496/496
(100 %)
4 diff
(99.2 %id)
AW503753 lymph ATXN2L.h 1126 to 1504 1 to 379       379/379
(100 %)
4 diff
(99.0 %id)
TI_154150950   ATXN2L.h 1132 to 1757 79 to 702       624/632
(98 %)
16 diff
(97.5 %id)
BM904236 lymph, lymphoma, cell line ATXN2L.h 1321 to 1965 1 to 651       651/922
(70 %)
13 diff
(98.6 %id)
BE549391 cervical carcinoma cell line, cervix ATXN2L.h 2500 to 2917 1 to 427       427/427
(100 %)
22 diff
(94.9 %id)
AW028969 poorly differentiated adenocarcinoma withsignet ring cell features, stomach ATXN2L.h 2531 to 2924 395 to 1       395/443
(89 %)
15 diff
(96.7 %id)
AI955787 adenocarcinoma, Pancreas ATXN2L.h 2533 to 2926 394 to 2       393/394
(99 %)
0 diff
(100 %id)
AA505300 breast ATXN2L.h 2536 to 2926 397 to 7   tiling clone,   391/397
(98 %)
0 diff
(100 %id)
AA775659 heart ATXN2L.h 2544 to 2919 376 to 1       376/376
(100 %)
0 diff
(100 %id)
AW276057 lung, two pooled squamous cell carcinomas ATXN2L.h 2544 to 2926 386 to 4       383/608
(62 %)
0 diff
(100 %id)
AI347779 2 pooled tumors (clear cell type), Kidney ATXN2L.h 2550 to 2921 373 to 2       372/373
(99 %)
0 diff
(100 %id)
AW058618 pooled ATXN2L.h 2551 to 2924 374 to 1       374/374
(100 %)
0 diff
(100 %id)
AW084983 esophagus, squamous cell carcinoma ATXN2L.h 2551 to 2919 368 to 1       368/368
(100 %)
3 diff
(99.2 %id)
BU631848 cell lines, Chondrosarcoma ATXN2L.h 2553 to 2924 390 to 19   AAA Possibly primed on the genome, locally A rich (21/24 A in genome downstream of last aligned base) 372/372
(100 %)
3 diff
(99.2 %id)
AI520776 adenocarcinoma, Pancreas ATXN2L.h 2554 to 2921 368 to 3       366/398
(91 %)
0 diff
(100 %id)
AI167222 pooled ATXN2L.h 2555 to 2918 364 to 1       364/364
(100 %)
0 diff
(100 %id)
AI758712 poorly-differentiated endometrialadenocarcinoma, 2 pooled tumors, uterus ATXN2L.h 2555 to 2916 397 to 36   AAA Possibly primed on the genome, locally A rich (21/24 A in genome downstream of last aligned base) 362/365
(99 %)
0 diff
(100 %id)
AI660540 thymus, pooled ATXN2L.h 2555 to 2924 370 to 1       370/370
(100 %)
3 diff
(99.2 %id)
AW193056 adenocarcinoma, Pancreas ATXN2L.h 2564 to 2919 357 to 1       357/361
(98 %)
13 diff
(96.4 %id)
AI350445 pooled germ cell tumors ATXN2L.h 2570 to 2895 326 to 1       326/331
(98 %)
0 diff
(100 %id)
R38908 whole brain ATXN2L.h 2572 to 2924 365 to 11   AAA Possibly primed on the genome, locally A rich (21/24 A in genome downstream of last aligned base) 355/359
(98 %)
3 diff
(99.2 %id)
CN480132 Knee, Osteoarthritic Cartilage ATXN2L.h 2574 to 2924 369 to 19   AAA Possibly primed on the genome, locally A rich (21/24 A in genome downstream of last aligned base) 351/351
(100 %)
0 diff
(100 %id)
AA766335 germinal center B cell ATXN2L.h 2575 to 2919 359 to 15   AAA Possibly primed on the genome, locally A rich (21/24 A in genome downstream of last aligned base) 345/345
(100 %)
3 diff
(99.2 %id)
AI032047 liver and spleen ATXN2L.h 2576 to 2914 339 to 1       339/340
(99 %)
0 diff
(100 %id)
R38834 whole brain ATXN2L.h 2577 to 2924 360 to 11       350/360
(97 %)
0 diff
(100 %id)
AW089094 brain, tumor, 5 pooled (see description) ATXN2L.h 2578 to 2920 348 to 1       348/349
(99 %)
9 diff
(97.5 %id)
CA312349 Human Lung Epithelial cells, lung ATXN2L.h 2578 to 2914 360 to 24   AAA   337/342
(98 %)
0 diff
(100 %id)
AW005139 thymus, pooled ATXN2L.h 2584 to 2924 351 to 11   AAA Possibly primed on the genome, locally A rich (21/24 A in genome downstream of last aligned base) 341/350
(97 %)
2 diff
(99.5 %id)
AI354634 poorly differentiated adenocarcinoma withsignet ring cell features, stomach ATXN2L.h 2585 to 2920 336 to 1       336/336
(100 %)
1 diff
(99.8 %id)
AW951313   ATXN2L.h 2595 to 2924 1 to 330   AAA Possibly primed on the genome, locally A rich (21/24 A in genome downstream of last aligned base) 330/330
(100 %)
1 diff
(99.7 %id)
BF345492 anaplastic oligodendroglioma with 1p/19qloss, brain ATXN2L.h 2608 to 2919 1 to 310   AAA Possibly primed on the genome, locally A rich (21/24 A in genome downstream of last aligned base) 310/310
(100 %)
2 diff
(99.4 %id)
R38837 whole brain ATXN2L.h 2616 to 2926 322 to 8       315/322
(97 %)
0 diff
(100 %id)
AI004512   ATXN2L.h 2620 to 2757 139 to 2       138/139
(99 %)
0 diff
(100 %id)
AI538502 B-cell, chronic lymphotic leukemia ATXN2L.h 2620 to 2758 139 to 1       139/139
(100 %)
2 diff
(98.6 %id)
AI868211 poorly differentiated adenocarcinoma withsignet ring cell features, stomach ATXN2L.h 2620 to 2924 305 to 1       305/305
(100 %)
2 diff
(99.4 %id)
AI620025 moderately-differentiated endometrialadenocarcinoma, 3 pooled tumors, uterus ATXN2L.h 2620 to 2919 300 to 1       300/300
(100 %)
11 diff
(96.4 %id)
AW029059 poorly differentiated adenocarcinoma withsignet ring cell features, stomach ATXN2L.h 2620 to 2921 305 to 1       305/305
(100 %)
5 diff
(98.4 %id)
AW271243 Kidney ATXN2L.h 2620 to 2758 139 to 1       139/139
(100 %)
3 diff
(97.9 %id)
AW261974 lung, two pooled squamous cell carcinomas ATXN2L.h 2625 to 2920 296 to 1       296/301
(98 %)
17 diff
(94.4 %id)
AA435793.
matches multiple genes
  ATXN2L.h 2632 to 2924 293 to 1     also hits gene ARHGEF4 293/293
(100 %)
0 diff
(100 %id)
AA992046   ATXN2L.h 2632 to 2924 303 to 11   AAA Possibly primed on the genome, locally A rich (21/24 A in genome downstream of last aligned base) 293/293
(100 %)
2 diff
(99.4 %id)
BI831115 brain, medulla ATXN2L.h 2633 to 2919 1 to 285   AAA Possibly primed on the genome, locally A rich (21/24 A in genome downstream of last aligned base) 285/285
(100 %)
4 diff
(98.6 %id)
DB520673 testis ATXN2L.h 2652 to 2919 1 to 268     Submitted on the opposite strand 268/268
(100 %)
4 diff
(98.6 %id)
AI804813 serous papillary carcinoma, high grade, 2pooled tumors, uterus ATXN2L.h 2663 to 2919 257 to 1       257/257
(100 %)
0 diff
(100 %id)
AW452315   ATXN2L.h 2666 to 2886 238 to 18   AAA Possibly primed on the genome, locally A rich (21/24 A in genome downstream of last aligned base) 221/221
(100 %)
0 diff
(100 %id)
AA568480 colon, colon tumor RER+ ATXN2L.h 2669 to 2924 273 to 18   AAA Possibly primed on the genome, locally A rich (21/24 A in genome downstream of last aligned base) 256/256
(100 %)
3 diff
(98.9 %id)
AI985665 uterus, well-differentiated endometrialadenocarcinoma, 7 pooled tumors ATXN2L.h 2671 to 2919 249 to 1       249/249
(100 %)
1 diff
(99.6 %id)
AW001379 colon, colonic mucosa from 3 patients with Crohn'sdisease ATXN2L.h 2676 to 2921 250 to 5       246/267
(92 %)
0 diff
(100 %id)
AA480371 colon ATXN2L.h 2677 to 2919 243 to 1       243/243
(100 %)
0 diff
(100 %id)
AW007538 adenocarcinoma, Pancreas ATXN2L.h 2679 to 2926 249 to 2       248/249
(99 %)
0 diff
(100 %id)
BG056876 anaplastic oligodendroglioma, brain ATXN2L.h 2680 to 2926 247 to 1       247/247
(100 %)
0 diff
(100 %id)
BQ548613 insulinoma, Pancreas ATXN2L.h 2681 to 2919 255 to 17   AAA Possibly primed on the genome, locally A rich (21/24 A in genome downstream of last aligned base) 239/245
(97 %)
0 diff
(100 %id)
BQ548906 insulinoma, Pancreas ATXN2L.h 2681 to 2919 8 to 246   AAA Possibly primed on the genome, locally A rich (21/24 A in genome downstream of last aligned base) 239/246
(97 %)
9 diff
(96.4 %id)
CK826275 insulinoma, Pancreas ATXN2L.h 2681 to 2919 255 to 17   AAA Possibly primed on the genome, locally A rich (21/24 A in genome downstream of last aligned base) 239/245
(97 %)
0 diff
(100 %id)
AA379986 skin ATXN2L.h 2732 to 2897 170 to 5     Submitted on the opposite strand 166/170
(97 %)
0 diff
(100 %id)
D45600 lung ATXN2L.h 2738 to 2926 1 to 189     Submitted on the opposite strand 189/190
(99 %)
2 diff
(99.0 %id)
CB105814 Liver ATXN2L.h 2746 to 2926 1 to 181       181/184
(98 %)
1 diff
(99.5 %id)
BE047432 ovary, serous papillary tumor ATXN2L.h 2772 to 2924 153 to 1       153/153
(100 %)
0 diff
(100 %id)
BE049435 adenocarcinoma, Pancreas ATXN2L.h 2787 to 2921 135 to 1       135/135
(100 %)
0 diff
(100 %id)
BQ435407 leiomyosarcoma, uterus ATXN2L.i 1 to 653 1 to 652   tiling clone,   652/850
(76 %)
8 diff
(99.1 %id)
DA320744 hippocampus ATXN2L.i 13 to 563 2 to 553   capped   552/552
(100 %)
1 diff
(99.9 %id)
BQ054531 lymph, lymphoma, cell line ATXN2L.i 279 to 1237 20 to 983       964/1066
(90 %)
30 diff
(97.2 %id)
BQ055282 lymph, lymphoma, cell line ATXN2L.i 279 to 773 21 to 515       495/1458
(33 %)
12 diff
(99.2 %id)
BQ056315 lymph, lymphoma, cell line ATXN2L.i 279 to 1240 23 to 993       971/1040
(93 %)
26 diff
(97.5 %id)
BQ065473 lymph, lymphoma, cell line ATXN2L.i 279 to 1144 20 to 891       872/1022
(85 %)
18 diff
(98.3 %id)
DA806726 brain ATXN2L.i 323 to 889 2 to 568   capped   567/567
(100 %)
0 diff
(100 %id)
CN394682 embryonic stem cells, cell lines H1, H7, andH9 ATXN2L.i 364 to 1128 1 to 765       765/765
(100 %)
2 diff
(99.8 %id)
CN394683 embryonic stem cells, cell lines H1, H7, andH9 ATXN2L.i 370 to 994 1 to 625       625/625
(100 %)
1 diff
(99.9 %id)
DB084184 testis ATXN2L.i 381 to 947 2 to 568   capped   567/567
(100 %)
0 diff
(100 %id)
BM452778 lymph, lymphoma, cell line ATXN2L.i 382 to 1281 1 to 913   tiling clone,   913/1074
(85 %)
17 diff
(98.5 %id)
BI225691 Burkitt lymphoma, lymph ATXN2L.i 839 to 1573 1 to 730       730/731
(99 %)
11 diff
(98.5 %id)
BI225868 Burkitt lymphoma, lymph ATXN2L.i 839 to 1516 1 to 677   tiling clone,   677/677
(100 %)
4 diff
(99.5 %id)
BE270216 Burkitt lymphoma, lymph ATXN2L.i 859 to 1509 1 to 648       648/648
(100 %)
6 diff
(99.1 %id)
BE396556 Burkitt lymphoma, lymph ATXN2L.i 859 to 1516 1 to 656   tiling clone,   656/763
(85 %)
12 diff
(98.5 %id)
BE513755 Burkitt lymphoma, lymph ATXN2L.i 859 to 1524 1 to 664   tiling clone,   664/733
(90 %)
14 diff
(98.1 %id)
BE561295 Burkitt lymphoma, lymph ATXN2L.i 859 to 1579 1 to 713   tiling clone,   713/811
(87 %)
16 diff
(98.1 %id)
BE560067 Burkitt lymphoma, lymph ATXN2L.i 860 to 1540 1 to 686   tiling clone,   684/686
(99 %)
14 diff
(98.0 %id)
BE560740 Burkitt lymphoma, lymph ATXN2L.i 861 to 1586 1 to 718       718/829
(86 %)
16 diff
(98.1 %id)
BE269578 Burkitt lymphoma, lymph ATXN2L.i 1031 to 1496 1 to 464       464/464
(100 %)
7 diff
(98.5 %id)
CX166796 human embryonic stem cells differentiated toan early endodermal cell type ATXN2L.i 1526 to 2256 1 to 731   tiling clone,   731/731
(100 %)
1 diff
(99.9 %id)
BC029964 Brain, adult medulla ATXN2L.j 1 to 1542 1542 to 1   tiling clone, available from MGC, Submitted on the opposite strand 1542/1542
(100 %)
1 diff
(100.0 %id)
BI829793 brain, medulla ATXN2L.j 860 to 1542 680 to 1   available from MGC, Submitted on the opposite strand 680/680
(100 %)
4 diff
(99.5 %id)
TI_57176359   ATXN2L.j 860 to 1550 744 to 57     Submitted on the opposite strand 688/744
(92 %)
3 diff
(99.6 %id)
DA795043 brain ATXN2L.k 1 to 551 2 to 552   tiling clone, capped   551/551
(100 %)
1 diff
(99.9 %id)
DA919542 small intestine ATXN2L.k 10 to 254 2 to 247   tiling clone, capped   246/248
(99 %)
5 diff
(98.0 %id)
BC050437 Peripheral Nervous System, sciatic nerve ATXN2L.k 294 to 3566 215 to 3487 exact tiling clone, AAA Possibly primed on the genome, locally A rich (21/24 A in genome downstream of last aligned base) 3273/3487
(93 %)
0 diff
(100 %id)
BQ956385 sciatic nerve ATXN2L.k 294 to 920 214 to 848       635/885
(71 %)
17 diff
(98.1 %id)
CT000106 T-Lymphocytes ATXN2L.l 1 to 645 1 to 645   tiling clone,   645/645
(100 %)
0 diff
(100 %id)
BQ336065 marrow ATXN2L.l 343 to 571 1 to 224       224/226
(99 %)
22 diff
(90.3 %id)
DR159028 human embryonic stem cells differentiated toan early endodermal cell type ATXN2L.l 567 to 1379 1 to 814   tiling clone,   814/814
(100 %)
1 diff
(99.9 %id)
CV799583 Blastocyst, pluripotent cell line derived fromblastocyst inner cell mass ATXN2L.l 1161 to 1824 729 to 74   tiling clone, AAA Submitted on the opposite strand 656/807
(81 %)
15 diff
(98.2 %id)
AF070605 brain ATXN2L.m 1 to 1934 1 to 1934 exact tiling clone, AAA Possibly primed on the genome, locally A rich (21/24 A in genome downstream of last aligned base) 1934/1934
(100 %)
0 diff
(100 %id)
BM723589 eye, fetal eyes, lens, eye anterior segment,optic nerve, retina, Retina Foveal and Macular, RPE andChoroid ATXN2L.m 1154 to 1829 1 to 676       676/789
(85 %)
3 diff
(99.7 %id)
TI_149279408   ATXN2L.m 1223 to 1929 795 to 89   AAA Possibly primed on the genome, locally A rich (21/24 A in genome downstream of last aligned base) 707/708
(99 %)
18 diff
(97.5 %id)
BU678825 lung, Primary Lung Epithelial Cells ATXN2L.m 1383 to 1929 565 to 19   AAA Possibly primed on the genome, locally A rich (21/24 A in genome downstream of last aligned base) 547/547
(100 %)
1 diff
(99.9 %id)
BG984051 colon_normal ATXN2L.n 1 to 477 9 to 486   tiling clone,   478/486
(98 %)
10 diff
(98.0 %id)
BF736061 bladder_tumor ATXN2L.n 476 to 897 17 to 438   tiling clone,   422/438
(96 %)
6 diff
(98.7 %id)
AL042086 testis ATXN2L.n 805 to 1257 1 to 454   tiling clone,   454/455
(99 %)
16 diff
(96.5 %id)
EB386637 eye, optic nerve ATXN2L.n 1082 to 1867 1 to 786   tiling clone,   786/786
(100 %)
1 diff
(99.9 %id)
BF760819 colon ATXN2L.n 1212 to 1662 469 to 19     Submitted on the opposite strand 451/469
(96 %)
24 diff
(94.9 %id)
BF948151 nervous_normal ATXN2L.n 1263 to 1646 78 to 460       383/460
(83 %)
6 diff
(98.7 %id)
AL549933 placenta, Placenta Cot 25-normalized ATXN2L.n 1567 to 2054 1 to 501   tiling clone,   501/619
(80 %)
18 diff
(97.1 %id)
AL574047 placenta, Placenta Cot 25-normalized ATXN2L.n 2151 to 2991 864 to 14   tiling clone,   846/1061
(79 %)
31 diff
(97.1 %id)
CX758060 Blastocyst, pluripotent cell line derived fromblastocyst inner cell mass ATXN2L.o 1 to 712 1 to 705   tiling clone, Submitted on the opposite strand 702/767
(91 %)
12 diff
(98.5 %id)
CB250510 Human Lung Epithelial cells, lung ATXN2L.o 698 to 1465 785 to 19   tiling clone, AAA Possibly primed on the genome, locally A rich (21/24 A in genome downstream of last aligned base) 767/767
(100 %)
3 diff
(99.7 %id)
BU633435 cell lines, Chondrosarcoma ATXN2L.o 960 to 1465 524 to 19   AAA Possibly primed on the genome, locally A rich (21/24 A in genome downstream of last aligned base) 506/506
(100 %)
0 diff
(100 %id)
BG280739 melanotic melanoma, skin ATXN2L.p 1 to 769 1 to 771   tiling clone,   771/825
(93 %)
19 diff
(97.7 %id)
BE276160 melanotic melanoma, skin ATXN2L.p 21 to 537 1 to 517       517/517
(100 %)
0 diff
(100 %id)
BE389517 endometrium, adenocarcinoma cell line, uterus ATXN2L.p 21 to 641 1 to 624       624/624
(100 %)
12 diff
(98.1 %id)
BE384336 melanotic melanoma, skin ATXN2L.p 21 to 553 1 to 533   tiling clone,   533/533
(100 %)
0 diff
(100 %id)
AW243891 serous papillary carcinoma, high grade, 2pooled tumors, uterus ATXN2L.p 494 to 1105 613 to 1   tiling clone,   613/613
(100 %)
9 diff
(98.6 %id)
AI671811 pooled germ cell tumors ATXN2L.p 569 to 1090 522 to 1       522/522
(100 %)
0 diff
(100 %id)
AI651881 pooled germ cell tumors ATXN2L.p 569 to 1090 522 to 1       522/522
(100 %)
1 diff
(99.9 %id)
AI917517 pooled germ cell tumors ATXN2L.p 574 to 1090 516 to 1       516/516
(100 %)
1 diff
(99.9 %id)
AI371971 pooled germ cell tumors ATXN2L.p 623 to 1091 469 to 1   tiling clone,   469/469
(100 %)
0 diff
(100 %id)
CA952736 Pancreas, Purified pancreatic islet ATXN2L.p 856 to 1090 1 to 235   fully sequenced, AAA Possibly primed on the genome, locally A rich (17/17 A in genome downstream of last aligned base) 235/235
(100 %)
0 diff
(100 %id)
CA952491 Pancreas, Purified pancreatic islet ATXN2L.p 891 to 1089 199 to 1   fully sequenced, Possibly primed on the genome, locally A rich (17/17 A in genome downstream of last aligned base) 199/199
(100 %)
0 diff
(100 %id)
CN398986 embryonic stem cells, DMSO-treated H9 cellline ATXN2L.q 1 to 644 1 to 643 H3I Q5R A6H P7L Q8R ... tiling clone,   643/643
(100 %)
3 diff
(99.6 %id)
DN993079 brain, whole brain ATXN2L.r 1 to 609 9 to 615   tiling clone,   607/615
(98 %)
8 diff
(98.7 %id)
CD703296 normal nasopharynx ATXN2L.r 465 to 912 14 to 458   tiling clone,   445/458
(97 %)
9 diff
(98.1 %id)
BG957759 colon ATXN2L.r 714 to 995 1 to 287   tiling clone,   287/287
(100 %)
16 diff
(94.5 %id)
BX327083 Neuroblastoma Cot 25-normalized ATXN2L.r 869 to 1691 826 to 1 N2* tiling clone, Submitted on the opposite strand 826/876
(94 %)
19 diff
(97.9 %id)
TI_149299822   ATXN2L.s 1 to 906 982 to 71 G3A A5S G6P P7H L9W ... tiling clone, AAA Possibly primed on the genome, locally A rich (21/24 A in genome downstream of last aligned base) 905/1003
(90 %)
21 diff
(98.0 %id)
AW003513 pooled germ cell tumors ATXN2L.t 1 to 603 604 to 1 V113G R114* tiling clone,   604/604
(100 %)
6 diff
(99.1 %id)
BM757117 Ascites, stomach ATXN2L.u 1 to 471 1 to 471 exact tiling clone,   471/471
(100 %)
0 diff
(100 %id)
DA729544   ATXN2L.va 1 to 520 2 to 521   tiling clone, capped   520/520
(100 %)
0 diff
(100 %id)
AW163308 brain, frontal lobe ATXN2L.va 234 to 338 1 to 105       105/105
(100 %)
0 diff
(100 %id)
TI_149293258   ATXN2L.va 382 to 1046 750 to 84   tiling clone, AAA Possibly primed on the genome, locally A rich (21/24 A in genome downstream of last aligned base) 667/957
(69 %)
4 diff
(99.6 %id)
BU682501 lung ATXN2L.va 524 to 1046 541 to 19   AAA Possibly primed on the genome, locally A rich (21/24 A in genome downstream of last aligned base) 523/523
(100 %)
0 diff
(100 %id)
AA714127 germinal center B-cells, tonsil ATXN2L.va 566 to 1053 488 to 2       487/488
(99 %)
0 diff
(100 %id)
AA572716   ATXN2L.va 567 to 1003 1 to 436       436/436
(100 %)
7 diff
(98.4 %id)
AI802630 colon, colonic mucosa from 5 ulcerative colitispatients ATXN2L.va 571 to 1014 442 to 1       442/447
(98 %)
17 diff
(96.2 %id)
AI435264 B-cell, chronic lymphotic leukemia ATXN2L.va 574 to 1047 474 to 1       474/474
(100 %)
0 diff
(100 %id)
BY994572   ATXN2L.va 574 to 1053 516 to 37     Submitted on the opposite strand 480/635
(75 %)
0 diff
(100 %id)
AA907138 germinal center B cell ATXN2L.va 578 to 1053 478 to 3       476/487
(97 %)
0 diff
(100 %id)
AA858406 colon, colon tumor ATXN2L.va 578 to 1046 469 to 1       469/469
(100 %)
0 diff
(100 %id)
AA605120 adrenal adenoma, adrenal gland ATXN2L.va 579 to 1045 467 to 1       467/470
(99 %)
0 diff
(100 %id)
AA868392   ATXN2L.va 580 to 1048 471 to 3       469/471
(99 %)
0 diff
(100 %id)
AA812745   ATXN2L.va 581 to 1051 481 to 11   AAA Possibly primed on the genome, locally A rich (21/24 A in genome downstream of last aligned base) 471/471
(100 %)
0 diff
(100 %id)
BQ187300 eye, fetal eyes, lens, eye anterior segment,optic nerve, retina, Retina Foveal and Macular, RPE andChoroid ATXN2L.va 587 to 1053 16 to 481   tiling clone,   466/514
(90 %)
2 diff
(99.7 %id)
TI_151734276   ATXN2L.va 587 to 1051 560 to 95   AAA Possibly primed on the genome, locally A rich (21/24 A in genome downstream of last aligned base) 466/937
(49 %)
2 diff
(99.8 %id)
AW157511 brain, frontal lobe ATXN2L.va 591 to 1053 469 to 6       464/473
(98 %)
0 diff
(100 %id)
CN398988 embryonic stem cells, cell lines H1, H7, andH9 ATXN2L.va 594 to 1023 1 to 430       430/430
(100 %)
3 diff
(99.4 %id)
BI022341 marrow ATXN2L.va 599 to 891 294 to 1       294/294
(100 %)
10 diff
(96.6 %id)
CA975990 sciatic nerve ATXN2L.va 607 to 1046 1 to 440   AAA Possibly primed on the genome, locally A rich (21/24 A in genome downstream of last aligned base) 440/440
(100 %)
0 diff
(100 %id)
AI273355 adenocarcinoma, colon ATXN2L.va 608 to 1046 439 to 1       439/439
(100 %)
4 diff
(99.1 %id)
AI683245 serous papillary carcinoma, high grade, 2pooled tumors, uterus ATXN2L.va 616 to 1051 436 to 1       436/436
(100 %)
3 diff
(99.4 %id)
AI087062 B-cell, chronic lymphotic leukemia ATXN2L.va 619 to 1014 395 to 1       395/395
(100 %)
5 diff
(98.8 %id)
AI679173 poorly differentiated adenocarcinoma withsignet ring cell features, stomach ATXN2L.va 620 to 1046 426 to 1       426/426
(100 %)
4 diff
(99.1 %id)
AA569150 colon, colon tumor RER+ ATXN2L.va 623 to 1048 426 to 1       426/426
(100 %)
1 diff
(99.8 %id)
CN398987 embryonic stem cells, DMSO-treated H9 cellline ATXN2L.va 633 to 1023 11 to 401       391/401
(97 %)
6 diff
(98.6 %id)
AI683614 uterus, well-differentiated endometrialadenocarcinoma, 7 pooled tumors ATXN2L.va 634 to 1033 413 to 14   AAA Possibly primed on the genome, locally A rich (21/24 A in genome downstream of last aligned base) 400/400
(100 %)
2 diff
(99.5 %id)
AI690732 serous papillary carcinoma, high grade, 2pooled tumors, uterus ATXN2L.va 636 to 1048 414 to 2       413/414
(99 %)
0 diff
(100 %id)
AI201255   ATXN2L.va 637 to 1053 419 to 3       417/419
(99 %)
0 diff
(100 %id)
AI686941 poorly-differentiated endometrialadenocarcinoma, 2 pooled tumors, uterus ATXN2L.va 637 to 1046 410 to 1       410/410
(100 %)
0 diff
(100 %id)
BG251653 adenocarcinoma, cell line, Liver ATXN2L.va 643 to 1013 1 to 368   AAA Possibly primed on the genome, locally A rich (21/24 A in genome downstream of last aligned base) 368/368
(100 %)
3 diff
(99.2 %id)
AI305815 2 pooled tumors (clear cell type), Kidney ATXN2L.va 647 to 1048 403 to 2       402/403
(99 %)
0 diff
(100 %id)
CD674949 eye, lens ATXN2L.vb 1 to 489 1 to 489 exact tiling clone,   489/489
(100 %)
4 diff
(99.2 %id)
AL561354 B cells from Burkitt lymphoma ATXN2L.vc 1 to 784 1 to 796 exact tiling clone, fully sequenced,   796/796
(100 %)
10 diff
(98.8 %id)
AL582593 B cells from Burkitt lymphoma ATXN2L.vc 377 to 783 413 to 1   tiling clone, fully sequenced,   413/413
(100 %)
8 diff
(98.1 %id)
BX956077   ATXN2L.vd 1 to 521 84 to 604 N23S tiling clone,   521/604
(86 %)
7 diff
(98.9 %id)
BE815339 breast_normal ATXN2L.ve 1 to 329 328 to 2 exact tiling clone,   327/328
(99 %)
0 diff
(100 %id)
BQ269480 Pancreas, Purified pancreatic islet ATXN2L.vf-u 1 to 481 3 to 488   tiling clone, fully sequenced,   486/488
(99 %)
14 diff
(97.2 %id)
BQ787279 Pancreas, Purified pancreatic islet ATXN2L.vf-u 39 to 484 1 to 448   fully sequenced,   448/448
(100 %)
6 diff
(98.7 %id)
CA841147 Pancreas, Purified pancreatic islet ATXN2L.vf-u 59 to 429 1 to 372   tiling clone,   372/379
(98 %)
2 diff
(99.5 %id)
AA249100   ATXN2L.vf-u 334 to 618 1 to 283 exact tiling clone,   283/283
(100 %)
3 diff
(99.0 %id)
BQ286124 Pancreas, Purified pancreatic islet ATXN2L.vf-u 451 to 901 451 to 1   tiling clone, fully sequenced,   451/451
(100 %)
0 diff
(100 %id)
BQ786998 Pancreas, Purified pancreatic islet ATXN2L.vf-u 454 to 901 447 to 1   fully sequenced,   447/447
(100 %)
1 diff
(99.8 %id)
CA840896 Pancreas, Purified pancreatic islet ATXN2L.vf-u 467 to 901 435 to 1       435/435
(100 %)
1 diff
(99.8 %id)
AV737087 cord Blood ATXN2L.vf-u 515 to 894 1 to 371   AAA Possibly primed on the genome, locally A rich (18/20 A in genome downstream of last aligned base) 371/372
(99 %)
7 diff
(98.2 %id)
CV802230 Blastocyst, pluripotent cell line derived fromblastocyst inner cell mass ATXN2L.vg-u 1 to 734 1 to 725 exact tiling clone,   725/850
(85 %)
11 diff
(98.8 %id)
DB331861 small intestine ATXN2L.vh-u 1 to 557 558 to 1 T12X E61K tiling clone,   558/558
(100 %)
15 diff
(97.4 %id)
DB526002 testis ATXN2L.vh-u 139 to 557 1 to 419   tiling clone, Submitted on the opposite strand 419/419
(100 %)
0 diff
(100 %id)
AW082689 pooled ATXN2L.vi-u 1 to 489 490 to 1 A46P M47H E48G N49E D50R ... tiling clone,   490/490
(100 %)
2 diff
(99.6 %id)
GD151485   ATXN2L.vi-u 396 to 498 1 to 103   tiling clone,   103/107
(96 %)
4 diff
(96.3 %id)
GD151490   ATXN2L.vi-u 396 to 486 1 to 91   AAA Possibly primed on the genome, locally A rich (12/12 A in genome downstream of last aligned base) 91/91
(100 %)
1 diff
(99.0 %id)
BI059475 uterus_tumor ATXN2L.vj-u 1 to 273 1 to 273 Q44H tiling clone,   273/273
(100 %)
2 diff
(99.3 %id)
BI061849 uterus_tumor ATXN2L.vj-u 1 to 273 1 to 273 Q44H     273/273
(100 %)
2 diff
(99.3 %id)
BQ329338 lung_normal ATXN2L.vj-u 77 to 464 1 to 392   tiling clone,   392/394
(99 %)
14 diff
(96.5 %id)
BI024865 marrow ATXN2L.vk-u 1 to 388 1 to 394 R7S A36S L37P Y38F G39M ... tiling clone,   394/394
(100 %)
11 diff
(97.3 %id)
AA909902 pooled ATXN2L.vl-u 1 to 384 384 to 1 exact tiling clone,   384/384
(100 %)
1 diff
(99.8 %id)
AA906126 pooled ATXN2L.vl-u 49 to 384 336 to 1   tiling clone,   336/336
(100 %)
0 diff
(100 %id)
AA323289 brain, cerebellum Gene ATXN2L, variant not shown         This clone was ignored    
AF034373 brain Gene ATXN2L, variant not shown       AAA This clone was ignored    
AY188334   Gene ATXN2L, variant not shown       AAA This clone was ignored    
AY188335   Gene ATXN2L, variant not shown       AAA This clone was ignored    
AY188336   Gene ATXN2L, variant not shown       AAA This clone was ignored    
AY188337   Gene ATXN2L, variant not shown       AAA This clone was ignored    
AY188338   Gene ATXN2L, variant not shown       AAA Suspected internal deletion, suspected internal deletion, this clone was ignored    
N35873 melanocyte Gene ATXN2L, variant not shown         Submitted on the opposite strand, submitted on the opposite strand    
BE560406 Burkitt lymphoma, lymph Gene ATXN2L, variant not shown         Suspected internal deletion, this clone was ignored    
BC068012 Skin, melanotic melanoma. Gene ATXN2L, variant not shown       available from MGC, AAA Suspected internal deletion, this clone was ignored    
BU195367 melanotic melanoma, skin Gene ATXN2L, variant not shown       available from MGC, Suspected internal deletion, this clone was ignored    
U70671   Gene ATXN2L, variant not shown       AAA This clone was ignored    
? Gene Summary Gene on genome mRNA:.a, .b, .c, .d, .e, .f, .g, .h, .i, .j, .k, .l, .m, .n, .o, .p, .q, .r, .s, .t, .u, .va, .vb, .vc, .vd, .ve, .vf-u, .vg-u, .vh-u, .vi-u, .vj-u, .vk-u, .vl-u Alternative mRNAs features, proteins, introns, exons, sequences Expression Tissue Function, regulation, related genes DCI